The (S)-enantiomer of 2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride, commonly recognized as the dihydrochloride monohydrate salt of pramipexole, is supplied as a white to off-white crystalline powder with a molecular formula C₁₀H₁₉Cl₂N₃S·H₂O and a molecular weight of
302.26 g/mol. Its CAS registry number is
104632-25-9 for the anhydrous dihydrochloride. The compound exhibits a specific optical rotation [α]²⁰/D of approximately
−67° to
−69° (c = 1, methanol) when enantiomeric purity exceeds
99.0% enantiomeric excess. As a non-ergoline dopamine agonist, the (S)-configuration at the 6-position of the tetrahydrobenzothiazole ring is an absolute requirement for D₂ and D₃ receptor affinity; the (R)-isomer shows a reduction in binding potency by more than two orders of magnitude. Routine quality control for research-grade and pharmaceutical intermediate lots incorporates chiral HPLC analysis on an amylose tris(3-chloro-4-methylphenylcarbamate) stationary phase with a mobile phase of n-hexane/ethanol/diethylamine
80:20:0.1 v/v/v, achieving a limit of quantification for the undesired R-enantiomer of
0.05% area area. This strict stereochemical control distinguishes the product from racemic mixtures or crude free-base materials that often contain residual propylamine and incomplete cyclization by-products.
Why the Dihydrochloride Salt Offers a Wider Processing Window in Aqueous Formulation Compared to the Monohydrochloride
The monohydrochloride salt of pramipexole is known to undergo partial dissociation at pH values above
5.0, leading to precipitation of the poorly water-soluble free base. In contrast, the dihydrochloride salt maintains complete solubility in water at concentrations exceeding
250 mg/mL across a pH range of
2.0 to
6.5, measured using a USP <711> dissolution apparatus with paddle stirring at
50 rpm and
37°C. Dynamic vapor sorption analysis conducted at
25°C across a relative humidity gradient of
0–90% (SMS DVS Intrinsic, ICH Q1A guidelines) shows a weight gain of
0.8% for the dihydrochloride monohydrate at
60% RH, versus a gain of
2.3% for a monohydrochloride sample with comparable particle size distribution. The difference becomes critical in high-shear wet granulation processes where localized moisture uptake during binder addition can initiate amorphous phase transitions; the dihydrochloride salt exhibits a glass transition temperature of the amorphous fraction above
110°C as determined by modulated DSC, delaying crystallization-driven agglomeration until a water activity of
0.75. Table 1 below provides comparative equilibrium solubility data in common granulation fluids.
Comparative Solubility of Pramipexole Salt Forms in Granulation Solvents at 25°C
| Solvent System | Dihydrochloride Solubility (mg/mL) | Monohydrochloride Solubility (mg/mL) |
|---|
| Purified Water, pH 4.0 | 285 ± 12 | 190 ± 15 |
| Water:Ethanol 70:30 v/v | 210 ± 9 | 85 ± 11 |
| Water:Isopropanol 60:40 v/v | 175 ± 10 | 62 ± 8 |
The enhanced solubility margin of the dihydrochloride directly affects the maximum drug loading achievable in extended-release matrix tablets manufactured on a rotary press; feedback from production-scale trials on a Fette 3090i press with
16-station tooling indicates that granule sticking to punch faces is eliminated when the formulation’s liquid saturation ratio is kept below
0.65, a condition maintained only with the higher-solubility salt form at the intended dose of
1.5 mg per tablet.
Chiral Purity Thresholds That Govern Dopamine D₃ Receptor Autoradiography Selectivity
In quantitative autoradiography experiments using human post-mortem caudate-putamen tissue sections, the selectivity ratio of D₃ over D₂ receptor binding is critically dependent on the enantiomeric purity of the radioligand’s cold reference standard. For displacement assays with [³H]-(S)-pramipexole, the presence of
0.3% (R)-enantiomer increases nonspecific binding by approximately
15% at
0.1 nM ligand concentration, as the (R)-isomer possesses weak affinity for sigma-1 sites. Therefore, the dihydrochloride product is released only after chiral chromatography verification with an acceptance criterion of enantiomeric excess ≥
99.5%. Simultaneous monitoring of the (R)-enantiomer at retention time
8.7 min against the (S)-peak at
11.2 min on a Daicel Chiralpak AD-H column (
250 mm ×
4.6 mm,
5 µm) under isocratic conditions ensures batch-to-batch stereochemical consistency. This level of purity distinguishes the lot from generic “pramipexole HCl” materials that may carry up to
1.0% of the optical antipode and are not qualified for in vitro pharmacology work where subtype discrimination is paramount. Each shipment includes a Certificate of Analysis referencing the chromatographic conditions, column lot number, and the specific rotation value measured on a Rudolph Autopol VI digital polarimeter calibrated with NIST-traceable quartz control plates.
Where the dihydrochloride salt demonstrates its advantage over unbuffered free-base material is in the preparation of stock solutions for microdialysis probe calibration. The free base requires sonication-assisted dissolution in acidified saline and degrades by
2–3% over
6 h at ambient temperature as measured by LC-MS/MS peak area count decline. The dihydrochloride, dissolved at
10 mM in artificial cerebrospinal fluid (aCSF:
147 mM NaCl,
2.7 mM KCl,
1.2 mM CaCl₂,
0.85 mM MgCl₂, pH
7.4), remains stable with less than
0.5% degradation over
24 h stored in polypropylene vials at
4°C. This stability window is essential for in vivo recovery experiments lasting overnight.
When the Free Base Presents Handling Difficulties: Salt Formation and Polymorph Control at the 50-L Scale
Direct isolation of the free base of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole from reductive amination reaction mixtures yields a viscous oil that solidifies slowly at −
20°C. The semi-solid nature precludes efficient filtration on an 0.5 m² Hastelloy Nutsche filter-dryer, resulting in product loss exceeding
15% of theoretical yield. Salt formation with
2.05 equivalents of anhydrous hydrogen chloride in isopropanol at
0–10°C instantaneously precipitates the dihydrochloride monohydrate as a filterable crystalline solid with a median particle size of
35–50 µm (Malvern Mastersizer 3000) when the antisolvent addition rate is controlled at
2 L/h into a
50 L glass-lined reactor. The crystallization is exothermic; the jacket temperature is maintained at −
5°C with a ramp rate not exceeding
0.3°C/min during nucleation to prevent oiling out. A significant operational boundary exists: if the chloride content by silver nitrate titration falls below
18.9% w/w (target
19.2% for the dihydrochloride monohydrate), mixed salt phases appear, reducing aqueous solubility by
40%. Inline Raman spectroscopy using a Kaiser RXN2 probe with a
785 nm laser monitors the disappearance of the free base C=N stretch at
1620 cm⁻¹ to determine reaction endpoint. Drying under vacuum at
40°C for
16 h with nitrogen bleeding achieves a water content of
3.0–4.5% by Karl Fischer (ASTM E203-16), consistent with the monohydrate stoichiometry. Deviations in drying temperature above
50°C induce partial dehydration and concomitant amorphous formation, detected as a
1–2 J/g exotherm in the DSC thermogram near
120°C, which correlates with a
0.2% reduction in assay value during subsequent long-term stability storage at
25°C/60% RH.
An Auditable Impurity Profile for Regulatory Starting Material Submissions
The dihydrochloride salt is frequently positioned as an Active Pharmaceutical Ingredient (API) starting material under ICH Q11 when the synthetic route employs it as the penultimate intermediate before final purification. In this context, the analytical package must address mutagenic impurities, elemental contaminants, and residual solvents to the thresholds specified in ICH M7 and Q3D. Table 2 provides a consolidated impurity control strategy typical for GMP-compliant lots released in accordance with EU GMP Part II.
Impurity Control Specifications for (S)-2-Amino-4,5,6,7-Tetrahydro-6-(Propylamino)Benzothiazole Dihydrochloride
| Parameter | Method Reference | Acceptance Limit |
|---|
| Assay (anhydrous, solvent-free) | HPLC, USP <621>, C18, 262 nm | 98.0–102.0% |
| Related Substances (total) | HPLC gradient, same as Assay | ≤0.5% |
| Unspecified Impurity | HPLC | ≤0.10% |
| Enantiomeric Purity | Chiral HPLC, Chiralpak AD-H | ≥ 99.0% ee |
| Water Content | Karl Fischer coulometry, ASTM E203 | 3.0–4.5% w/w |
| Residue on Ignition | USP <281> | ≤0.1% |
| Heavy Metals (Class 1, 2A, 2B) | ICP-MS, ICH Q3D | As, Cd, Hg, Pb each ≤5 ppm; total Class 1/2A ≤10 ppm |
| Residual Methanol | Headspace GC, USP <467> Procedure A | ≤3000 ppm |
| Residual Isopropanol | Headspace GC | ≤5000 ppm |
| N-Nitrosopramipexole | LC-MS/MS, negative APCI | ≤0.03 ppm (FDA guidance, Feb 2021) |
The specific concern with N-nitrosopramipexole arises from the secondary propylamine moiety; formation risk is mitigated by avoiding nitrite sources during salt formation and by tracking nitrite levels in process water to
≤0.05 ppm via ion chromatography (EPA Method 300.1). This proactive control differentiates the product from legacy dihydrochloride batches that lacked nitrosamine risk assessments prior to the ICH M7 addendum.
In forced degradation studies conducted on the dihydrochloride salt to validate stability-indicating capability of the HPLC method (ICH Q2(R1)), the compound is exposed to
0.1 N HCl at
80°C for
24 h,
0.1 N NaOH at
25°C for
4 h, and
3% hydrogen peroxide at
25°C for
24 h. Under alkaline stress, the primary degradation route is depropylation at the
6-position, yielding (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole as the major impurity at up to
8.2% area. Oxidative stress produces the sulfoxide derivative (retention time
5.4 min relative to pramipexole at
9.2 min) and the sulfone at
3.1 min; mass balance closure is typically ≥
97%. Thermal stress at
105°C over
7 days shows no degradation beyond
0.3% total impurities, confirming that the hydrated salt’s lattice energy suppresses solid-state thermal reactivity. The free base, lacking the stabilizing chloride counterion network, decomposes by
4.5% under the same dry heat condition. These forced degradation data are included in the technical dossier available for each lot, alongside the HPLC peak purity factor of the main peak, which must be ≥
999 (Waters Empower 3 software, PDA detector threshold angle) to demonstrate spectral homogeneity. Laboratories performing quantitative NMR for orthogonal assay verification use a Varian 600 MHz spectrometer with the dihydrochloride dissolved in DMSO-d₆; integration of the methine proton at the chiral center (δ
3.45 ppm, multiplet) against a certified internal standard of 1,4-dinitrobenzene provides an assay precision of
±0.5%.
